Rapport Therapeutics, Inc. Common Stock Earnings Dividend

Rapport Therapeutics, Inc. Common Stock’s revenue jumped +Inf% since last year same period to $20Mn in the Q1 2026. On a quarterly growth basis, Rapport Therapeutics, Inc. Common Stock has generated +Inf% jump in its revenue since last 3-months.

Rapport Therapeutics, Inc. Common Stock’s net profit jumped 17.48% since last year same period to $-19.86Mn in the Q1 2026. On a quarterly growth basis, Rapport Therapeutics, Inc. Common Stock has generated 41.19% jump in its net profits since last 3-months.

Rapport Therapeutics, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -99.29% in the Q1 2026. On a quarterly growth basis, Rapport Therapeutics, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.

Rapport Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.93 - a -30.99% fall from last quarter’s estimates.

Rapport Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.93.

Rapport Therapeutics, Inc. Common Stock’s earning per share (EPS) jumped 38.24% since last year same period to -0.42 in the Q1 2026. This indicates that the Rapport Therapeutics, Inc. Common Stock has generated 38.24% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Rapport Therapeutics, Inc. Common Stock’s return on assets (ROA) stands at -0.19.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Rapport Therapeutics, Inc. Common Stock’s return on equity (ROE) stands at -0.28.